INTERVIEW: Alcobra CEO discusses novel ADHD path
This article was originally published in Scrip
Executive Summary
Alcobra CEO Yaron Daniely admits that drug development for attention deficit hyperactivity disorder (ADHD) is a "road well-traveled," but says his Tel Aviv, Israel-based company is forging a new path and will confirm the efficacy of its drug metadoxine (MDX) around the end of September.